US Drugmaker Actavis to Spend 85 Billion on Irish Rival

US Drugmaker Actavis to Spend $8.5 Billion on Irish Rival

Deal will create a specialty pharmaceutical company with approximately $11 billion in combined annual revenue, focused on women's health, gastroenterology, urology and dermatology.

DUBLIN -- U.S. pharmaceutical company Actavis has agreed to an all-stock takeover of Irish rival Warner Chilcott, the pair announced on Monday.

"Actavis, Inc. and Warner Chilcott plc today announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion," a joint statement said.

The deal will create "a leading global specialty pharmaceutical company with approximately $11 billion in combined annual revenue" -- focused on women's health, gastroenterology, urology and dermatology, the companies said.

"We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," said Actavis chief executive Paul Bisaro.

"The combination of Actavis and Warner Chilcott creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential, and is supported by a deep pipeline of development programs," he added.

Copyright Agence France-Presse, 2013

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish